Citi Analysts Maintain Buy Rating on Rigel with $67 Price Target

Rigel Pharmaceuticals (RIGL) received a Buy rating and a $67 price target from Citi analyst Yigal Nochomovitz. The analyst has a 4.8% average return and a 40% success rate on recommended stocks. Rigel's latest earnings release showed a quarterly revenue of $53.33 million and a net profit of $11.45 million. The company's shares opened today at $27.18.

Rigel Pharmaceuticals (RIGL) has recently received a positive analyst upgrade from Citi analyst Yigal Nochomovitz, who assigned a Buy rating and a $67 price target to the company's stock. This move follows a series of positive updates from other analysts and strong earnings reports. The company's latest earnings release showed a quarterly revenue of $53.33 million and a net profit of $11.45 million, demonstrating robust financial performance.

Analyst Kristen Kluska of Cantor Fitzgerald has also been bullish on Rigel Pharmaceuticals. She maintained a Neutral rating on the stock but significantly raised the price target from $23.00 to $32.00, representing a 39.13% increase [1]. This adjustment follows a previous increase in May 2025, where the price target was raised from $20.00 to $23.00 [1].

The Wall Street consensus is generally positive, with an average target price of $33.74 and a brokerage recommendation of "Outperform" [1]. Rigel's pipeline includes several promising drug candidates, such as TAVALISSE (fostamatinib disodium hexahydrate) tablets, which is the only oral spleen tyrosine kinase (SYK) inhibitor, and R289, a dual IRAK1/4 inhibitor [1].

Rigel Pharmaceuticals is expected to report a 141.4% increase in revenue for the period ending June 30, 2025, with earnings of $2.58 per share, according to analyst estimates [2]. The company's shares opened today at $27.18, indicating a slight increase from the previous close.

The company's strong financial performance and positive analyst sentiment suggest that Rigel Pharmaceuticals is well-positioned to continue its growth trajectory. Investors should closely monitor the company's earnings reports and pipeline developments for further insights into its future prospects.

References:
[1] https://www.gurufocus.com/news/3040807/cantor-fitzgerald-raises-price-target-for-rigl-to-3200-maintains-neutral-rating-rigl-stock-news
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TT396:0-rigel-pharmaceuticals-inc-expected-to-post-earnings-of-2-58-a-share-earnings-preview/